Roivant and Immunovant announce positive Phase 3 batoclimab MG results and initial Phase 2b CIDP results

Roivant Sciences Ltd.

Phase 3 MG study met primary endpoint with 5.6-point MG-ADL improvement at 12 weeks in high-dose batoclimab arm.
Initial CIDP Phase 2b Period 1 data showed 1.8-point aINCAT improvement and 84% responder rate in patients with ≥70% IgG reduction.
Immunovant plans to initiate registrational studies for IMVT-1402 in MG and CIDP.
Deeper IgG reductions correlated with better clinical outcomes across both studies.
Conference call held on March 19, 2025 at 8:00 a.m. ET to discuss results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.